1 / 5

P rimary End Point (CV death, MI and stroke at 15 months)

P rimary End Point (CV death, MI and stroke at 15 months). Clopidogrel Prasugrel. 15. 12.4. P =0.02 RRR=21%. 10.0. 10. 9.5. P =0.002 RRR=32%. Proportion of patients (%). 6.5. 5. HR=0.79 (0.65 – 0.97) NNT=42. Age-adjusted HR=0.81 (0.66-0.99). 0. 0. 50. 100. 150. 200. 250.

perdy
Download Presentation

P rimary End Point (CV death, MI and stroke at 15 months)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Primary End Point (CV death, MI and stroke at 15 months) Clopidogrel Prasugrel 15 12.4 P=0.02 RRR=21% 10.0 10 9.5 P=0.002 RRR=32% Proportion of patients (%) 6.5 5 HR=0.79 (0.65–0.97) NNT=42 Age-adjusted HR=0.81 (0.66-0.99) 0 0 50 100 150 200 250 300 350 400 450 Time (days) Adapted from Montalescot et al. ESC 2008.

  2. Efficacy End Points at 15 Months Clopidogrel Prasugrel 14 P=0.02 P=0.03 P=0.007 12 P=0.02 10 8 Proportion of population (%) P=0.11 6 P=0.09 4 P=0.02 2 0 All Death MI UTVR Stent Thrombosis* CV Death/MI CV Death/ MI/UTVR CV Death/ MI/Stroke * ARC def/probable Adapted from Montalescot et al. ESC 2008.

  3. 3 2.8 2.4 2 1.6 Proportion of patients (%) 1.2 1 0 0 100 200 300 400 Time (Days) Stent thrombosis ARC Definite/probable Clopidogrel Prasugrel P=0.02 RRR=42% P=0.008 RRR=51% HR=0.58 (0.36–0.93) NNT=83 Age-adjusted HR=0.59 (0.37-0.96) Adapted from Montalescot et al. ESC 2008.

  4. TIMI major non-CABG bleeding Clopidogrel Prasugrel 2.5 P=0.65 2.4 2.0 2.1 1.5 Proportion of patients (%) 1.0 0.5 HR=1.11 (0.70–1.77) NNH=333 Age-adjusted HR=1.19 (0.75-1.89) 0 0 100 200 300 400 Time (Days) Adapted from Montalescot et al. ESC 2008.

  5. Hazard Ratios for Primary and Other End Points, Prasugrel vs. Clopidogrel, for Nondiabetics and Diabetics in TRITON-TIMI 38 *primary end point AdaptedfromWiviottet al. Circulation2008; available at: http://circ.ahajournals.org.

More Related